Duration of protection against clinical malaria provided by three regimens of intermittent preventive treatment in Tanzanian infants

Matthew Cairns, Roly Gosling, Ilona Carneiro, Samwel Gesase, Jacklin F Mosha, Ramadhan Hashim, Harparkash Kaur, Martha Lemnge, Frank W Mosha, Brian Greenwood, Daniel Chandramohan, Matthew Cairns, Roly Gosling, Ilona Carneiro, Samwel Gesase, Jacklin F Mosha, Ramadhan Hashim, Harparkash Kaur, Martha Lemnge, Frank W Mosha, Brian Greenwood, Daniel Chandramohan

Abstract

Background: Intermittent preventive treatment in infants (IPTi) is a new malaria control tool. However, it is uncertain whether IPTi works mainly through chemoprophylaxis or treatment of existing infections. Understanding the mechanism is essential for development of replacements for sulfadoxine-pyrimethamine (SP) where it is no longer effective. This study investigated how protection against malaria given by SP, chlorproguanil-dapsone (CD) and mefloquine (MQ), varied with time since administration of IPTi.

Methods and findings: A secondary analysis of data from a randomised, placebo-controlled trial in an area of high antifolate resistance in Tanzania was conducted. IPTi using SP, CD, MQ or placebo was given to 1280 infants at 2, 3 and 9 months of age. Poisson regression with random effects to adjust for potential clustering of malaria episodes within children was used to calculate incidence rate ratios for clinical malaria in defined time strata following IPTi. The short-acting antimalarial CD gave no protection against clinical malaria, whereas long-acting MQ gave two months of substantial protection (protective efficacy (PE) 73.1% (95% CI: 23.9, 90.5) and 73.3% (95% CI: 0, 92.9) in the first and second month respectively). SP gave some protection in the first month after treatment (PE 64.5% (95% CI: 10.6, 85.9)) although it did not reduce the incidence of malaria up to 12 months of age. There was no evidence of either long-term protection or increased risk of malaria for any of the regimens.

Conclusion: Post-treatment chemoprophylaxis appears to be the main mechanism by which IPTi protects children against malaria. Long-acting antimalarials are therefore likely to be the most effective drugs for IPTi, but as monotherapies could be vulnerable to development of drug resistance. Due to concerns about tolerability, the mefloquine formulation used in this study is not suitable for IPTi. Further investigation of combinations of long-acting antimalarials for IPTi is needed.

Trial registration: Clinicaltrials.gov NCT00158574.

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Figure 1. Protective efficacy of SP against…
Figure 1. Protective efficacy of SP against clinical malaria.
Protective efficacy (1- rate ratio vs. placebo) is shown by month since treatment. Y-axes for IPT2 and IPT3 graphs are truncated at -300, for full extent of confidence interval see table 2.
Figure 2. Protective efficacy of CD against…
Figure 2. Protective efficacy of CD against clinical malaria.
Protective efficacy (1- rate ratio vs. placebo) is shown by month since treatment. Y-axes for IPT2 and IPT3 graphs are truncated at -150, for full extent of confidence interval see table 2.
Figure 3. Protective efficacy of MQ against…
Figure 3. Protective efficacy of MQ against clinical malaria.
Protective efficacy (1- rate ratio vs. placebo) is shown by month since treatment. Y-axes for IPT2 and IPT3 graphs are truncated at -150, for full extent of confidence interval see table 2.

References

    1. Committee on the Perspectives on the Role of Intermittent Preventive Treatment for Malaria in Infants. Assessment of the Role of Intermittent Preventive Treatment for Malaria in Infants: Letter Report. National Academies Press 2008
    1. Aponte JJ, Schellenberg D, Egan A, Breckenridge A, Carneiro I, et al. Efficacy and safety of intermittent preventive treatment with sulfadoxine-pyrimethamine for malaria in African infants: a pooled analysis of six randomised, placebo-controlled trials. Lancet. 2009;374:1533–1542.
    1. Greenwood B. Review: Intermittent preventive treatment - a new approach to the prevention of malaria in children in areas with seasonal malaria transmission. Tropical Medicine & International Health. 2006;11:983–991.
    1. ter Kuile FO, van Eijk AM, Filler SJ. Effect of sulfadoxine-pyrimethamine resistance on the efficacy of intermittent preventive therapy for malaria control during pregnancy: a systematic review. Jama. 2007;297:2603–2616.
    1. Schellenberg D, Menendez C, Kahigwa E, Aponte J, Vidal J, et al. Intermittent treatment for malaria and anaemia control at time of routine vaccinations in Tanzanian infants: a randomised, placebo-controlled trial. Lancet. 2001;357:1471–1477.
    1. Schellenberg D, Menendez C, Aponte JJ, Kahigwa E, Tanner M, et al. Intermittent preventive antimalarial treatment for Tanzanian infants: follow-up to age 2 years of a randomised, placebo-controlled trial. Lancet. 2005;365:1481–1483.
    1. Chandramohan D, Owusu-Agyei S, Carneiro I, Awine T, Amponsa-Achiano K, et al. Cluster randomised trial of intermittent preventive treatment for malaria in infants in area of high, seasonal transmission in Ghana. British Medical Journal. 2005;331:727–733.
    1. Macete E, Aide P, Aponte JJ, Sanz S, Mandomando I, et al. Intermittent preventive treatment for malaria control administered at the time of routine vaccinations in Mozambican infants: A randomized, placebo-controlled trial. Journal of Infectious Diseases. 2006;194:276–285.
    1. Kobbe R, Kreuzberg C, Adjei S, Thompson B, Langefeld I, et al. A randomized controlled trial of extended intermittent preventive antimalarial treatment in infants. Clin Infect Dis. 2007;45:16–25.
    1. Mockenhaupt FP, Reither K, Zanger P, Roepcke F, Danquah I, et al. Intermittent preventive treatment in infants as a means of malaria control: a randomized, double-blind, placebo-controlled trial in northern Ghana. Antimicrob Agents Chemother. 2007;51:3273–3281.
    1. Grobusch MP, Lell B, Schwarz NG, Gabor J, Dornemann J, et al. Intermittent Preventive Treatment against Malaria in Infants in Gabon–A Randomized, Double-Blind, Placebo-Controlled Trial. J Infect Dis. 2007;196:1595–1602.
    1. White NJ. Intermittent presumptive treatment for malaria. PLoS Med. 2005;2:e3.
    1. Cairns M, Carneiro I, Milligan P, Owusu-Agyei S, Awine T, et al. Duration of Protection against Malaria and Anaemia Provided by Intermittent Preventive Treatment in Infants in Navrongo, Ghana. PLoS ONE. 2008;3:e2227.
    1. May J, Adjei S, Busch W, Gabor JJ, Issifou S, et al. Therapeutic and prophylactic effect of intermittent preventive anti-malarial treatment in infants (IPTi) from Ghana and Gabon. Malar J. 2008;7:198.
    1. Gosling RD, Gesase S, Mosha JF, Carneiro I, Hashim R, et al. Protective efficacy and safety of three antimalarial regimens for intermittent preventive treatment for malaria in infants: a randomised, double-blind, placebo-controlled trial. Lancet. 2009;374:1521–1532.
    1. Simpson JA, Hughes D, Manyando C, Bojang K, Aarons L, et al. Population pharmacokinetic and pharmacodynamic modelling of the antimalarial chemotherapy chlorproguanil/dapsone. Br J Clin Pharmacol. 2006;61:289–300.
    1. Karbwang J, White NJ. Clinical pharmacokinetics of mefloquine. Clin Pharmacokinet. 1990;19:264–279.
    1. Smith T, Felger I, Tanner M, Beck HP. Premunition in Plasmodium falciparum infection: insights from the epidemiology of multiple infections. Trans R Soc Trop Med Hyg. 1999;93(Suppl 1):59–64.
    1. Achtman AH, Bull PC, Stephens R, Langhorne J. Longevity of the immune response and memory to blood-stage malaria infection. Curr Top Microbiol Immunol. 2005;297:71–102.
    1. White NJ. Assessment of the pharmacodynamic properties of antimalarial drugs in vivo. Antimicrob Agents Chemother. 1997;41:1413–1422.
    1. Bødker R, Akida J, Shayo D, Kisinza W, Msangeni HA, et al. Relationship between altitude and intensity of malaria transmission in the Usambara Mountains, Tanzania. J Med Entomol. 2003;40:706–717.
    1. Schellenberg D, Menendez C, Aponte J, Guinovart C, Mshinda H, et al. The changing epidemiology of malaria in Ifakara Town, southern Tanzania. Trop Med Int Health. 2004;9:68–76.
    1. Guerra CA, Gikandi PW, Tatem AJ, Noor AM, Smith DL, et al. The limits and intensity of Plasmodium falciparum transmission: implications for malaria control and elimination worldwide. PLoS Med. 2008;5:e38.
    1. Gesase S, Gosling RD, Hashim R, Ord R, Naidoo I, et al. High resistance of Plasmodium falciparum to sulphadoxine/pyrimethamine in northern Tanzania and the emergence of dhps resistance mutation at Codon 581. PLoS ONE. 2009;4:e4569.
    1. Clayton D, Hills M. Oxford: Oxford University Press; 1993. Statistical Models in Epidemiology.
    1. Aubouy A, Fievet N, Bertin G, Sagbo JC, Kossou H, et al. Dramatically decreased therapeutic efficacy of chloroquine and sulfadoxine-pyrimethamine, but not mefloquine, in southern Benin. Trop Med Int Health. 2007;12:886–894.
    1. Mutabingwa T, Nzila A, Mberu E, Nduati E, Winstanley P, et al. Chlorproguanil-dapsone for treatment of drug-resistant falciparum malaria in Tanzania. Lancet. 2001;358:1218–1223.
    1. Kublin JG, Dzinjalamala FK, Kamwendo DD, Malkin EM, Cortese JF, et al. Molecular markers for failure of sulfadoxine-pyrimethamine and chlorproguanil-dapsone treatment of Plasmodium falciparum malaria. J Infect Dis. 2002;185:380–388.
    1. Watkins WM, Mberu EK, Winstanley PA, Plowe CV. The efficacy of antifolate antimalarial combinations in Africa: a predictive model based on pharmacodynamic and pharmacokinetic analyses. Parasitol Today. 1997;13:459–464.
    1. White NJ. How antimalarial drug resistance affects post treatment prophylaxis. Malar J. 2008;7:9.
    1. White NJ. The assessment of antimalarial drug efficacy. Trends Parasitol. 2002;18:458–464.
    1. Dzinjalamala FK, Macheso A, Kublin JG, Taylor TE, Barnes KI, et al. Association between the pharmacokinetics and in vivo therapeutic efficacy of sulfadoxine-pyrimethamine in Malawian children. Antimicrobial Agents and Chemotherapy. 2005;49:3601–3606.
    1. Stepniewska K, White NJ. Pharmacokinetic determinants of the window of selection for antimalarial drug resistance. Antimicrob Agents Chemother. 2008;52:1589–1596.
    1. White N. Antimalarial drug resistance and combination chemotherapy. Philos Trans R Soc Lond B Biol Sci. 1999;354:739–749.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅